{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+Albumin+2%25", "query": { "intervention": "Human Albumin 2%" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 125, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+Albumin+2%25&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T13:40:44.325Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02722304", "title": "Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease", "Alpha1-antitrypsin Deficiency" ], "interventions": [ { "name": "ARALAST NP 60 mg/kg", "type": "BIOLOGICAL" }, { "name": "ARALAST NP 120 mg/kg", "type": "BIOLOGICAL" }, { "name": "GLASSIA 60 mg/kg", "type": "BIOLOGICAL" }, { "name": "GLASSIA 120 mg/kg", "type": "BIOLOGICAL" }, { "name": "Human Albumin 2%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2016-11-02", "completion_date": "2018-09-14", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 14, "location_summary": "Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722304" }, { "nct_id": "NCT03147768", "title": "Laser Tissue Welding - Distal Pancreatectomy Sealing Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Tumor, Benign", "Pancreatic Neoplasms", "Pancreatic Adenocarcinoma", "Pancreatic Pseudocyst", "Pancreatic Neuroendocrine Tumor", "Pancreas; Insulinoma", "Pancreatic Cyst", "Pancreatic Teratoma", "Pancreatic Polypeptide Tumor", "Pancreatic Vipoma", "Pancreatic Cystadenoma", "Pancreas Injury", "Pancreatic Gastrinoma", "Pancreatic Glucagonoma" ], "interventions": [ { "name": "Distal Pancreatectomy Sealing Using LTW", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Laser Tissue Welding, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-01-01", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03147768" }, { "nct_id": "NCT02715531", "title": "A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 243, "start_date": "2016-04-06", "completion_date": "2021-05-31", "has_results": false, "last_update_posted_date": "2021-07-09", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 12, "location_summary": "Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02715531" }, { "nct_id": "NCT03387085", "title": "QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK for Infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-03-19", "completion_date": "2024-01-16", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387085" }, { "nct_id": "NCT03387111", "title": "QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Necitumumab", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-01-09", "completion_date": "2021-01-11", "has_results": true, "last_update_posted_date": "2024-08-05", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387111" }, { "nct_id": "NCT02503280", "title": "The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Ischemic Left Ventricular Dysfunction", "Myocardial Infarction" ], "interventions": [ { "name": "Autologous hMSCs", "type": "DRUG" }, { "name": "Autologous Human C-Kit CSCs II", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Biosense Webster MyoStar NOGA Injection Catheter System", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Joshua M Hare", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "21 Years to 89 Years" }, "enrollment_count": 0, "start_date": "2025-03-01", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02503280" }, { "nct_id": "NCT00684060", "title": "Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Left Ventricular Dysfunction" ], "interventions": [ { "name": "Adult stem cells", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 87, "start_date": "2008-07", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2015-07-10", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 5, "location_summary": "Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00684060" }, { "nct_id": "NCT04044690", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatomyositis" ], "interventions": [ { "name": "human immunoglobulin G", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2019-10-21", "completion_date": "2024-12-02", "has_results": true, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 15, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04044690" }, { "nct_id": "NCT06998940", "title": "Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Irinotecan Sucrosofate", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2026-05-13", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 274, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 207 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06998940" }, { "nct_id": "NCT03213964", "title": "Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "FATE-NK100", "type": "BIOLOGICAL" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 10, "start_date": "2017-10-19", "completion_date": "2021-03-10", "has_results": false, "last_update_posted_date": "2021-03-12", "last_synced_at": "2026-09-14T13:40:44.325Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03213964" } ] }